PRENETICS GLOBAL LTD-CL A
PRENASDAQTrading Snapshot
- Day Range
- $505.05 – $516.57
- 52-Week Range
- $7.18 – $23.63
- Volume
- $4.34B
- Avg Volume
- $3.57B
- Shares Outstanding
- 17.1M
- Next Earnings
- Sep 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $73M
- Last Q Revenue
- $18M
- P/E Ratio
- —
- P/S Ratio
- 4.4x
- EPS (TTM)
- $-3.30
- Dividend Yield
- —
Why Investors Own PRE
- ✓High-growth profile — revenue up +4.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PRENETICS GLOBAL LTD-CL A
A company profile for PRENETICS GLOBAL LTD-CL A isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings (NASDAQ:ADGM) stock
Prenetics Global: Path To Profitability On Course With Financing Deal
Prenetics Global trades near fair value now, with a potential 2028 upside if revenue targets and financing execution are achieved. See why PRE stock is a buy.
PRE Continues to Exceed Expectations and Receive Preferential Financing
By Brad Sorensen, CFA NASDAQ: PRE READ THE FULL PRE RESEARCH REPORT Prenetics Global (NASDAQ: PRE) delivered one of its most significant strategic financing announcements to date, securing a $1 billion growth financing commitment from General Catalyst's Customer Value Fund (CVF) for its rapidly expanding IM8 premium health and longevity brand. Rather than being a traditional financing
Benchmark Maintains Buy on Prenetics Global, Raises Price Target to $40
Benchmark analyst Bill Sutherland maintains Prenetics Global (NASDAQ:PRE) with a Buy and raises the price target from $30 to $40.
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks fell late Tuesday afternoon with the NYSE Healthcare Index declining 1.7% and the
Prenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF)
IM8 is the fastest-growing premium supplement brand ever recorded — over 50 million servings delivered to date, with approximately 200,000 servings currently delivered daily, and an order every 27 secondsPrenetics raises full-year 2026 IM8 revenue guidance to $210–220 million, up from $190–210 millionIM8 expected to reach $300 million in annualized run-rate revenue by year-end 2026IM8 expected to deliver $400 million or more in full-year 2027 revenueEvery $1 invested in customer acquisition has